The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study,” published in the April 2025 issue of BMC Urology by Huang et al. Researchers conducted a retrospective study to compare hyperthermic intravesical chemotherapy (HIVEC) using pirarubicin […]
The post Pirarubicin and BCG in Hyperthermic Intravesical Chemotherapy for High-Risk Bladder Cancer first appeared on Physician’s Weekly.
